ClinicalTrials.gg
CompletedNCT07922538Updated Nov 6, 2026

Human Bioequivalence Study of Letermovir Tablets

A Phase 1 interventional study of Generic Letermovir Tablet and Prevymis® in Tmax*(h), Cmax(ng/mL) and AUC0-t(ng∙h/mL), sponsored by The Affiliated Hospital of Qingdao University. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by The Affiliated Hospital of Qingdao University · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Dec 2023, registered Nov 2026).
Updated Nov 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study aimed to investigate the pharmacokinetics of a single oral dose of there test formulation letermovir tablets and the reference formulation letermovir tablets (Prymin®) in healthy adult subjects, and to evaluate the bioequivalence of the two formulations when taken orally after a meal.

02

Conditions studied

  • Tmax*(h)
  • Cmax(ng/mL)
  • AUC0-t(ng∙h/mL)
  • AUC0-∞(ng∙h/mL)
  • λz(h-1)
  • AUC_%Extrap(%)
03

In context

Lead sponsor

The Affiliated Hospital of Qingdao University is the lead sponsor of 150 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- 255/5000

  1. Before the trial, voluntarily sign the form and fully understand the trial content, process and possible adverse reactions;
  2. Be able to complete the study as required by the trial protocol;
  3. The subjects are willing to refrain from pregnancy, sperm donation or egg donation plans for 6 months after the last administration and to take effective measures voluntarily from the time of signing the informed consent (for female subjects, effective contraception measures have been taken within 14 days before the first administration of the drug);
  4. Age over 18 years old (including 18 years old) and without the need for reproduction, male and female subjects; Male subjects have a body weight of no less than 50.0 kg, female subjects have a body weight of no less than 45.0 kg, (BMI) = weight / height\^2 (kg/m\^2), and BMI is within the range of 19.0 - 26.0 kg/m\^2 (including the critical value).

Exclusion criteria

Exclusion Criteria:

  • 1) Those with serious medical histories such as heart disease, liver disease, kidney disease, digestive tract disorders, nervous system disorders, endocrine system disorders, respiratory system disorders, mental abnormalities, etc., as determined by the research doctor; 2) Those with abnormal conditions as determined by the clinical physician, including physical examinations, vital sign checks, or clinical laboratory tests, etc.; 3) Those with specific allergy histories (such as asthma), or currently suffering from allergic diseases (such as urticaria, eczema, etc.), or having an allergic constitution (such as being allergic to two or more drugs, foods such as milk or pollen), or known to be allergic to the components of this drug or its analogues; 4) Those with a history of swallowing difficulties or any gastrointestinal diseases that affect drug absorption (such as gastric or small intestine resection, atrophic gastritis, gastrointestinal bleeding, obstruction, etc.); 5) Pregnant women, lactating women, or those with positive pregnancy test results; 6) Those with positive results for surface antigen, antibody, antibody or syphilis antibody, or any one or more of them; 7) Those with a history of drug abuse within the past five years, or those who used drugs within three months before screening, or those with positive urine drug screening; 8) Those who consumed more than 14 units of alcohol per week on average (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine) within three months before screening, or those who could not stop alcohol intake during the period from the start of medication to the completion of blood sample collection, or those with positive alcohol breath test results; 9) Those who smoked more than 5 cigarettes per day within three months before screening or refused to use tobacco products during the screening period; 10) Those with a history of surgical operations within three months before screening, or those planning to undergo surgery during the study period; 11) Those who donated blood or had significant blood loss (> 400 mL, except for physiological blood loss in women) within three months before the first medication, or those who donated ≥ 2 treatment doses (1 treatment dose = 12 units of blood platelets) within one month before the medication; 12) Those who participated in any drug clinical trials and were taking medication within three months before the first medication; 13) Those who used any drug with interactions with ritonemivir (such as antibiotics: nifurpirin, anticonvulsants: carbamazepine, phenobarbital, phenytoin, anti-mycobacterial drugs: rifabutin, rifampicin, antipsychotics: thioridazine, endothelin antagonists: bosentan, herbal products: St. John's wort, HIV drugs: efavirenz, etravirine, nelfinavir, : cyclosporine, arousal-promoting drugs: modafinil, ergot alkaloids: ergotamine, dihydroergotamine, HMG-CoA reductase inhibitors: rosuvastatin, pitavastatin, simvastatin, pimozide, dabigatran) within 30 days before the first medication; 14) Those who received within 7 days before the first medication, or those planning to receive live attenuated vaccines during the trial; 15) Those who used any prescription drugs within 14 days before the first medication; 16) Those who used any over-the-counter drugs, Chinese herbal medicines or health supplements within 7 days before the first medication; 17) Those who took special diets (such as grapefruit and products containing grapefruit components) or engaged in intense exercise, or had other factors affecting drug absorption, distribution, metabolism, and excretion within 48 hours before the first medication; 18) Those who consumed any food rich in xanthine substances (such as coffee, tea, chocolate, cocoa, milk tea, etc.) within 48 hours before the first medication; 19) Those with difficulty in venous blood sampling or history of fainting or hemophilia; 20) Those with special dietary requirements and unable to follow the provided diet and corresponding regulations; Other subjects determined by the researchers to be unsuitable for participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Other
    Generic Letermovir Tablet

    Drug: Generic Letermovir Tablet

  • Other
    Prevymis

    Drug: Prevymis®

Interventions

  • DrugGeneric Letermovir Tablet

    Dometovir tablets produced domestically, with a specification of 240 mg per tablet, for oral administration, single dose administration. 240 mg (1 tablet), taken with 240 mL of warm water on an empty stomach.

  • Import the product Prethemis Tablets (trade name: PREVYMIS®), with a specification of 240 mg per tablet, for oral administration, single dose, 240 mg (1 tablet), taken with 240 mL of warm water on an empty stomach.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Letermovir

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose

  2. AUC0-t of Letermovir

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose

  3. AUC0-inf of Letermovir

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose

07

Study locations

1 site
  • Qingdao University Affiliated Hospital
    Qingdao, Shandong 266003, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jul 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 6, 2026
StartActual
Dec 1, 2023
Primary completionActual
Jul 25, 2024
CompletionActual
Jul 25, 2024
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07922538
Responsible party
Cao Yu (Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University) — Principal investigator
First posted
Nov 6, 2026
Start date
Dec 1, 2023
Primary completion
Jul 25, 2024
Completion
Jul 25, 2024
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion